Adaptive Biotechnologies Corporation

NasdaqGS:ADPT Stok Raporu

Piyasa değeri: US$692.1m

Adaptive Biotechnologies Yönetim

Yönetim kriter kontrolleri 2/4

Adaptive Biotechnologies CEO'su Chad Robins, Sep2009 tarihinde atandı, in görev süresi 15.17 yıldır. in toplam yıllık tazminatı $ 8.90M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.4% maaş ve 92.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.23% ine doğrudan sahiptir ve bu hisseler $ 8.51M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.2 yıl ve 8.8 yıldır.

Anahtar bilgiler

Chad Robins

İcra Kurulu Başkanı

US$8.9m

Toplam tazminat

CEO maaş yüzdesi7.4%
CEO görev süresi15.2yrs
CEO sahipliği1.2%
Yönetim ortalama görev süresi6.2yrs
Yönetim Kurulu ortalama görev süresi8.8yrs

Son yönetim güncellemeleri

Recent updates

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Jan 09
We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

CEO Tazminat Analizi

Chad Robins'un ücretlendirmesi Adaptive Biotechnologies'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$195m

Jun 30 2024n/an/a

-US$213m

Mar 31 2024n/an/a

-US$215m

Dec 31 2023US$9mUS$663k

-US$225m

Sep 30 2023n/an/a

-US$196m

Jun 30 2023n/an/a

-US$191m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$9mUS$658k

-US$200m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$229m

Dec 31 2021US$9mUS$639k

-US$207m

Sep 30 2021n/an/a

-US$190m

Jun 30 2021n/an/a

-US$171m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$597k

-US$146m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$99m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$3mUS$493k

-US$70m

Sep 30 2019n/an/a

-US$62m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$423k

-US$46m

Tazminat ve Piyasa: Chad 'nin toplam tazminatı ($USD 8.90M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.17M ).

Tazminat ve Kazançlar: Chad şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Chad Robins (50 yo)

15.2yrs

Görev süresi

US$8,904,267

Tazminat

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
$ 8.5m
Julie Rubinstein
President & COO6.8yrsUS$2.97m0.32%
$ 2.2m
Harlan Robins
Co-Founder & Chief Scientific Officer15.2yrsUS$8.61m0.69%
$ 4.8m
Sharon Benzeno
Chief Commercial Officer of Immune Medicine6.8yrsUS$2.88m0.22%
$ 1.5m
Christopher Carlson
Founderno dataVeri yokVeri yok
Kyle Piskel
VP, CFO & Principal Accounting Officer3.1yrsUS$1.66m0.10%
$ 723.8k
Karina Calzadilla
Vice President of Investor Relationsno dataVeri yokVeri yok
Francis Lo
Chief People Officer5.6yrsVeri yok0.17%
$ 1.2m
Susan Bobulsky
Chief Commercial Officer of MRD4.3yrsVeri yok0.17%
$ 1.2m
Mary Lancelotta
Senior Vice President of MRD BioPharma1.2yrsVeri yokVeri yok

6.2yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: ADPT 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.2 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
$ 8.5m
Peter Neupert
Lead Independent Director10.9yrsUS$355.00k0.093%
$ 647.1k
H. Parker
Member of Corporate Advisory Boardno dataVeri yokVeri yok
Michelle Griffin
Independent Director5.7yrsUS$330.00k0.035%
$ 243.6k
Robert Hershberg
Independent Director11.8yrsUS$325.00k0.051%
$ 356.3k
Michael Pellini
Independent Director6.8yrsUS$310.00k0.037%
$ 254.6k
Carol Gallagher
Member of Corporate Advisory Boardno dataVeri yokVeri yok
Craig Weissman
Member of Corporate Advisory Boardno dataVeri yokVeri yok
Graham Allen
Member of Corporate Advisory Boardno dataVeri yokVeri yok
Matthew Kahn
Member of Corporate Advisory Boardno dataVeri yokVeri yok
Katey Owen
Independent Director3.7yrsUS$310.00k0.038%
$ 263.2k

8.8yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ADPT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).